Current diagnosis of celiac disease (CeD) is inaccurate in patients following a gluten-free diet (GFD). Blood-based diagnostics targeting gluten-specific T cells, like tetramer assays, are highly sensitive and specific but are impractical for clinical use. We evaluated the potential of a simple whole blood assay measuring interleukin-2 release (WBAIL-2) for detecting gluten-specific T cells to aid in CeD diagnosis.

Gastrointestinal (GI) clinicians are a critical touchpoint for individuals at risk for genetic and familial syndromes that increase risk of colorectal, gastric and pancreatic cancer. While advances in sequencing technology and reduced costs have made genetic testing more readily accessible to clinicians and even to patients through direct-to-consumer testing, uptake of genetic testing remains underutilized. This is a missed opportunity to identify patients and family members who could benefit from genetic testing to diagnose cancer susceptibility syndromes for which surveillance and preventive interventions exist. Barriers for integration of genetic testing in routine practice include lack of awareness about genetic conditions by patients and providers, concerns about genetic testing costs and implications for insurability, as well as challenges in implementing algorithms for risk assessment and coordinated care in complex medical systems. This review addresses current evidence and guidelines for cancer risk assessment, genetic testing and management to enable GI clinicians to identify and care for individuals with genetic cancer-predisposition syndromes in routine practice.

In a treat to target era, objective disease assessment in inflammatory bowel disease (IBD) has become increasingly important. For many years, endoscopy has been generally accepted as the gold standard for evaluating the bowel mucosa, additionally facilitating biopsy. However, non-invasive disease assessment is now increasingly demanded and cross-sectional imaging techniques as well as video capsule endoscopy have markedly improved. Emerging evidence demonstrates the added clinical value of transmural assessment both in Crohn's disease and ulcerative colitis, and cross-sectional imaging modalities are increasingly used in phenotyping and monitoring IBD patients. In the current review we propose potential algorithms to use non-invasive imaging in various clinical scenarios and for use in daily practice. The readers will come away with an understanding of what imaging they should consider for different clinical situations and the strengths and limitations of each modality. Future developments of non-invasive diagnostic strategies and areas in need of further research are highlighted.

There is limited data on inflammatory bowel disease advanced therapy sequences. Therefore, we examined real-world advanced therapy sequences to compare persistence, healthcare use and costs in first-line advanced therapy.

ZBTB10 is a member of the zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing protein family, reported to be associated with tumorigenesis and progression. However, its specific roles in oncogenesis, prognosis, and immune infiltration in stomach adenocarcinoma (STAD) remain to be elucidated.

The prognostic significance of the Platelet-to-Lymphocyte Ratio (PLR) in patients with hepatocellular carcinoma (HCC) undergoing treatment with immune checkpoint inhibitors (ICIs) remains uncertain. A systematic review and meta-analysis was conducted to assess the prognostic value of PLR in HCC patients receiving ICIs.

Monogenic inflammatory bowel disease (mIBD) in patients with onset after the age of 16 has been increasingly recognized, but these reports are sporadic and lack a systematic overview, leaving the clinical and genetic characteristics poorly understood. This study aimed to characterize these late-onset mIBD (LO-mIBD), using an infantile-onset population as a control.

NDC80, a crucial component of the kinetochore, plays a pivotal role in regulating cell mitosis. Recent studies reported that NDC80 regulates the proliferation of cancer cells and may be related to poor prognosis in cancer. However, the biological function and mechanism of NDC80 in esophageal squamous cell carcinoma (ESCC) have not yet been elucidated. In this study, we analyzed the expression and mutation of NDC80 in ESCC tissue and assessed its impact on ESCC cells in vitro.

Small-bowel capsule endoscopy (SBCE) is an essential diagnostic tool for obscure gastrointestinal bleeding, particularly for identifying bleeding sources in the small intestine. The timing of SBCE is thought to affect its diagnostic yield; however, the optimal timing remains unknown.

Pepsinogen (PG) and gastrin-17 (G-17) are crucial in the gastric digestive processes. This study aimed to assess the diagnostic value of the serum PG and G-17 in identifying chronic atrophic gastritis (CAG) at different stages of severity under varying Helicobacter pylori (H. pylori) infection statuses.

Malignant hilar biliary obstruction is associated with a poor prognosis, making biliary drainage important for improving the quality of life. Endoscopic simultaneous side-by-side deployment of uncovered self-expandable metal stents is a novel approach. However, reliable clinical data on this method are limited. This retrospective, single-center study aimed to evaluate the feasibility, effectiveness, and safety of simultaneous side-by-side deployment of self-expandable metal stents for malignant hilar biliary obstruction.

To analyze the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC).

It was found that 33.8-52.5% of patients experienced nausea and vomiting after Transcatheter Arterial Chemoembolization (TACE) for liver cancer, based on prior literature. But there are no models that predict this risk. In this study, we investigated the factors associated with nausea and vomiting after TACE and developed a predictive model to predict these adverse events.

Inflammatory bowel disease (IBD) is an idiopathic disorder characterized by repeated relapses and remissions. Endoscopy, the gold standard for diagnosis and monitoring of these patients is time consuming, expensive, and invasive. Hence, faecal calprotectin (FCP) has been suggested as marker to determine the degree of intestinal inflammation and predict relapse in IBD.